CBD Global, LLC – World's Quality Source for Non-Psychoactive Cannabinoid Medicine

Hemoscreen™ Summary

(Cannabinoid Blood Tests)

This convenient and portable blood test kit is designed for clinical environments and for use by healthcare practitioners assisting and monitoring patient volunteers. Hemoscreen™ measures bioavailable absorption rates of medications and their associated blood concentration levels over time. These absorption rates change based on the delivery method of each unique product.

The first correlation of data associates a product to its measured max absorption. The second data set completes the bell curve showing the longevity and half-life of cannabinoids within the blood. The combined data is used to establish the most reasonably accurate dosage and regimen plans for patients that the cannabis industry has seen to date.

Hemoscreen™ is providing valuable information to further improve the ongoing development of efficacious cannabinoid medications.

Prague Facility

Extraction Science

Our exclusive European partnership provides direct access to:

A Schedule 1 Controlled Substance Licensed facility.

A sister Pharmaceutical research company for conducting clinical trials on cannabinoids and medical devices.

Standardized production of new Minor-Cannabinoid Predominant (MCP) oils and isolates (CBG, CBC, CBN, CBDV).

Synthetic CBD, CBC, and semi-synthetic CBN for research APIs.

An entire department of cannabis chemists focused on cutting edge research and innovation.

Close relationships with state authorities and regulators.

TrueNano™ Backscatter Sample Test Results

True Nano Water BackScatter Test 1 CBD Global

True Nano Water BackScatter Test 2 CBD Global

Research & Development

Education
Academic Collaboration
Genetic Species Development
Cell Culturing
Tissue Propagation
Clinical Studies & Patient Monitoring
Data Collection & Evaluation For Future R&D

Product Formulation

Research Data Analysis to Product Concept
Formulation & Production
Transparency Batch Tracking
In House Design & Development
In House Marketing & PR
Sales & Distribution (Wholesale & Retail)

Radioligand Binding Summary

(CB1/CB2 receptor binding affinity of cannabinoids)

The binding affinity of cannabinoids to their respective cell surface receptors (CB1/CB2) is being measured by using existing techniques of binding ligand molecules to cannabinoids and following them to specific, targeted sites. Successful binding is determined electrochemically or through fluorescence detection method. This form of analytic test identifies the presence of target molecules in a sample known to bind to receptors of interest.

This procedure is being utilized to identify any potential changes in binding affinity that may be caused by the differences between a patient receiving natural phytocannabinoids vs. derivative salts, isomers or synthesized versions. Additionally, changes in cellular metabolism may be seen between species of cannabis and their associated full plant spectrums.

Ultimately, this allows for the most accurate means of mapping specific forms of disease to patient demographics and the treatment values of different cannabis plant species. Physicians and health care practitioners can be better equipped to align and recommend the appropriate cannabis phenotype profiles for specific medicines needed by each unique patient.

EDITING TECHNIQUES USED

Sequenced Genome of specific cannabis strains

Sequenced Genome of specific cannabinoids (THC-A Synthase)

genetic transformation protocol via Chemical mutanagenesis

genetic transformation protocol via Gene gun editing

Completed protocol for Agrobacterium Mediated Transformation

Analytics & Testing

Pre/Post Harvest Potency Testing
Oils & Isolates Full Panel Testing (Potency, Solvents, Pesticides, Microbials, Metals)
Water Soluble Powders & Liquids Potency Testing
Finished Consumer Goods Potency Testing
Nano Particle Size Testing
Terpene Testing
2-AG/Anandamide, CBD/THC Metabolite Blood Analysis
Radioligand Binding Assays

Cultivation & Extraction

Controlled Breeding
Precision Cultivation
Harvesting/Storage
Extraction & Post Processing
Refinement/Distillation/Dewaxing/Isolation
Chain-of-Custody

Cultivated Seed Lot

Material Harvest Sheet

Safety Data Sheet

Seed Purchase Specs

Certificate Of Analysis

Certificate of Origin

US Department of Health and Human Services (HHS) - Patent US6630507B1

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidiol, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH3, and COCH3.

Read Entire Patent 507

REFINED CBG SAMPLE COA

Our New Site Will Be Up Soon